Wells Fargo raised the firm’s price target on Eli Lilly to $615 from $500 and keeps an Overweight rating on the shares. The firm thinks the success of SELECT data will likely increase uptake, persistence and access to obesity medicines such as Mounjaro. Recent ADA data also make Wells “comfortable” with Elli Lilly’s pipeline.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Lilly Completes Acquisition of DICE Therapeutics
- Eli Lilly upgraded to Buy from Hold at Jefferies
- Eli Lilly CEO: Top priority is to expand production of drugs like Mounjaro
- Eli Lilly price target raised to $580 from $490 at RBC Capital
- Novo Nordisk, Eli Lilly news positive for Terns Pharmaceuticals, says Mizuho